Part 1/8:
The Heart-Wrenching Decision on Sarepta Therapeutics' Drug for DMD
On April 25th, 2023, a significant event in the realm of pharmaceutical approvals took place when the FDA's advisory committee voted against recommending a new treatment developed by Sarepta Therapeutics for Duchenne Muscular Dystrophy (DMD). The decision, which resulted in a narrow 7 to 6 vote, serves as a poignant reminder of the high stakes involved in drug approvals, particularly for conditions as devastating as DMD, which affects a small patient population but comes with enormous emotional weight.